Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Sci Rep ; 9(1): 14082, 2019 10 01.
Artigo em Inglês | MEDLINE | ID: mdl-31575942

RESUMO

Nano-emulsions are promising carriers for antigen delivery. Here, we evaluated the efficacy of a water-oil nano-emulsion containing concentrated, inactivated Clostridium novyi (C. novyi) type B supernatant culture (nano-iCnB) in protecting Swiss mice against a lethal dose of alpha toxin concentrated extract. Proteins were confirmed in the nano-iCnB and their stabilities were determined according physical parameters such as Zeta Potential (ZP). Biochemical, hematological parameters and morphological appearance of liver, spleen and thigh muscle alterations were examined to determine the safety of the compound. Partial protection against lethal doses was achieved in immunized mice despite low IgG titers. These data suggest that our nano-emulsion is a simple and efficient method of promoting antigen delivery for toxin-related diseases.


Assuntos
Vacinas Bacterianas/administração & dosagem , Toxinas Botulínicas Tipo A/toxicidade , Clostridium , Animais , Vacinas Bacterianas/imunologia , Clostridium/imunologia , Feminino , Fígado/patologia , Camundongos , Nanopartículas , Baço/patologia , Vacinas de Produtos Inativados/administração & dosagem , Vacinas de Produtos Inativados/imunologia
2.
Toxins (Basel) ; 11(1)2019 01 12.
Artigo em Inglês | MEDLINE | ID: mdl-30642048

RESUMO

Botulinum neurotoxin type-A (BoNTA) is one of the seven different serotypes (A to G) produced by Clostridium botulinum. A stability-indicating size-exclusion chromatography (SEC) method was developed and validated, and the specificity was confirmed by forced degradation study, interference of the excipients, and peaks purity. The method was applied to assess the content and high-molecular-weight (HMW) forms of BoNTA in biopharmaceutical products, and the results were compared with those of the LD50 mouse bioassay, the T-47D cell culture assay, and the reversed-phase chromatography (RPC) method, giving mean values of 0.71% higher, 0.36% lower, and 0.87% higher, respectively. Aggregated forms showed significant effects on cytotoxicity, as well as a decrease in the bioactivity (p < 0.05). The employment of the proposed method in conjunction with the optimized analytical technologies for the analysis of the intact and altered forms of the biotechnology-derived medicines, in the correlation studies, enabled the demonstration of the capability of each one of the methods and allowed for great improvements, thereby assuring their safe and effective use.


Assuntos
Toxinas Botulínicas Tipo A/análise , Toxinas Botulínicas Tipo A/toxicidade , Animais , Bioensaio , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Cromatografia em Gel , Cromatografia Líquida , Cromatografia de Fase Reversa , Feminino , Humanos , Dose Letal Mediana , Camundongos , Reprodutibilidade dos Testes
3.
Braz. j. biol ; 77(2): 251-259, Apr.-June 2017. tab
Artigo em Inglês | LILACS | ID: biblio-888754

RESUMO

Abstract The treatment of sialorrhea is necessary for the constant risks posed by hypersalivation. A new therapeutic option comes up with the application of botulinum toxin in salivary glands. However, little is known about its mechanism of action in glandular tissue. Based on the above, this work had the objective to systematically review the literature about the action of botulinum toxin on submandibular and parotid salivary glands tissues. Electronic search was performed in databases of great relevance for this study (PubMed, SciELO, HighWire, Crossref, Scopus, Science Direct, MEDLINE, OLDMEDLINE, Serials Database, NLM Catalog, LILACS and IBECS). Inclusion and exclusion criteria for articles were established, and a total number of 14 articles were selected and used. There are few publications that clarify how the salivary gland acini behave with application of botulinum toxin. Although, the immunohistochemical findings were consistent among authors, showing weak immunoreactivity in glands treated with botulinum toxin. Histometric data are divergent, requiring more detailed studies to answer the questions about the efficacy and safety of botulinum toxin in salivary glands.


Resumo O tratamento da sialorreia se faz necessário pelos constantes riscos trazidos por este estado de hipersalivação. Uma nova opção terapêutica surge com a aplicação da toxina botulínica em glândulas salivares. Entretanto, pouco se sabe sobre o seu mecanismo de ação no tecido glandular. Com base no exposto, este trabalho teve o objetivo de revisar sistematicamente na literatura a ação da toxina botulínica sobre o tecido das glândulas salivares submandibular e parótida. Foi realizada uma busca eletrônica em bases de dados de grande relevância para este estudo (PubMed, SciELO, HighWire, Crossref, Scopus, Science Direct, MEDLINE, OLDMEDLINE, Serials Database, NLM Catalog, LILACS e IBECS). Foram estabelecidos critérios de inclusão e exclusão para os artigos, e um "n" de 14 trabalhos foram selecionados e utilizados. São poucas as publicações que esclarecem como os ácinos das glândulas salivares se comportam mediante aplicação da toxina botulínica. Apesar de os achados imunohistoquímicos entre os autores serem concordantes, com imunorreatividade mais fracas nas glândulas tratadas com a toxina botulínica, os dados histométricos são divergentes e há questionamentos metodológicos, necessitando de mais estudos pormenorizados para responder as questões sobre a eficácia e segurança da toxina botulínica nas glândulas salivares.


Assuntos
Animais , Coelhos , Ratos , Glândulas Salivares/fisiopatologia , Glândulas Salivares/patologia , Sialorreia/fisiopatologia , Sialorreia/patologia , Toxinas Botulínicas Tipo A/toxicidade , Sialorreia/induzido quimicamente
4.
Braz J Biol ; 77(2): 251-259, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27599097

RESUMO

The treatment of sialorrhea is necessary for the constant risks posed by hypersalivation. A new therapeutic option comes up with the application of botulinum toxin in salivary glands. However, little is known about its mechanism of action in glandular tissue. Based on the above, this work had the objective to systematically review the literature about the action of botulinum toxin on submandibular and parotid salivary glands tissues. Electronic search was performed in databases of great relevance for this study (PubMed, SciELO, HighWire, Crossref, Scopus, Science Direct, MEDLINE, OLDMEDLINE, Serials Database, NLM Catalog, LILACS and IBECS). Inclusion and exclusion criteria for articles were established, and a total number of 14 articles were selected and used. There are few publications that clarify how the salivary gland acini behave with application of botulinum toxin. Although, the immunohistochemical findings were consistent among authors, showing weak immunoreactivity in glands treated with botulinum toxin. Histometric data are divergent, requiring more detailed studies to answer the questions about the efficacy and safety of botulinum toxin in salivary glands.


Assuntos
Toxinas Botulínicas Tipo A/toxicidade , Glândulas Salivares/patologia , Glândulas Salivares/fisiopatologia , Sialorreia/patologia , Sialorreia/fisiopatologia , Animais , Coelhos , Ratos , Sialorreia/induzido quimicamente
5.
J Ocul Pharmacol Ther ; 29(4): 431-6, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23323889

RESUMO

PURPOSE: To verify the safety and efficacy of botulinum toxin type A (BoNT/A) to promote protective ptosis in dogs. METHODS: In this prospective interventional study, a total of 10 dogs underwent transcutaneous anterior chemodenervation of levator palpebral superioris with 15 U of BoNT/A. The systemic changes, ocular mobility, visual function, intraocular pressure (IOP), tear production, and the onset, degree, and duration of ptosis were evaluated on a daily basis during the first 7 days and on days 14, 21, and 28 after application. RESULTS: The onset of the clinical effect was observed between 2 and 3 days after application of the toxin; the time taken for maximum ptosis to develop varied from 4 to 7 days (mean 5 days) and the average duration of the toxin effect was 21 days. The mean percentage reduction in palpebral fissure height was 42.859% (SD±35.714%-59.821%). There was not a statistically significant difference in IOP before and after the BoNT/A application (P=0.974), or lacrimal production evaluation (P=0.276). There was no change in ocular mobility and no other adverse effect was observed in association with the administration of the study drug. CONCLUSION: The application of BoNT/A into the levator palpebral superioris muscle in dogs was effective and safe to promote protective ptosis with a temporary covering of the cornea.


Assuntos
Blefaroptose/induzido quimicamente , Toxinas Botulínicas Tipo A/farmacologia , Fármacos Neuromusculares/farmacologia , Animais , Toxinas Botulínicas Tipo A/toxicidade , Cães , Movimentos Oculares/efeitos dos fármacos , Feminino , Pressão Intraocular/efeitos dos fármacos , Masculino , Fármacos Neuromusculares/toxicidade , Estudos Prospectivos , Lágrimas/efeitos dos fármacos , Lágrimas/metabolismo , Fatores de Tempo
6.
Invest. clín ; 49(4): 469-486, dic. 2008. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-518677

RESUMO

En este estudio investigamos los cambios ultraestructurales a corto y largo plazo provocados por la toxina botulínica tipo A inyectada a dosis sub-letales in vivo en el levator auris longus de ratones. La neurotoxina actuó temporalmente sobre los terminales nerviosos e indujo una parálisis generalizada que afectó la morfología de la preparación neuromuscular estudiada influyendo sobre: tamaño y complejidad de la terminación nerviosa, población vesicular, apariencia de las mitocondrias, fisonomía de las células de Schwann, desarrollo y distribución de los pliegues de la membrana postsináptica, y morfología de los núcleos de los diferentes elementos de la placa motora. Además, la cantidad de tejido conectivo endomisial aumentó significativamente con relación a los casos control, siendo estos cambios marcados en las primeras semanas. Entre los 20 y 25 días, período correspondiente al proceso de recuperación observamos terminales nerviosos de apariencia variable, unos completamente degenerados rodeados por restos de prolongaciones de células de Schwann y otros nuevos contactos caracterizados ultraestructuralmente por su pequeño calibre y población vesicular escasa, rodeadas parcialmente por la célula de Schwann, axones tempranamente mielinizados, pliegues sinápticos escasamente desarrollados. Sesenta días posteriores a la inyección, el axón terminal recobró su apariencia normal: las vesículas sinápticas llenaban el axoplasma, las mitocondrias exhibían crestas y densidades electrónicas de apariencia habitual. Se puede concluir que la toxina botulínica tipo A provoca fenómenos de desnervación en el nervio terminal y en los componentes de la placa motora. Las células de Schwann juegan un papel importante en la recuperación morfofuncional de los terminales nerviosos y en su degradación.


Assuntos
Animais , Camundongos , Placa Motora , Células Musculares , Toxinas Botulínicas Tipo A/toxicidade
7.
Invest Clin ; 49(4): 469-86, 2008 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-19245166

RESUMO

We studied the short and long term ultrastructural changes produced by botulinum neurotoxin type A injected in vivo, at a sublethal dose, in mouse levator auris longus muscle. The neurotoxin had a temporary effect on nerve terminals which consisted in a generalized paralysis, that affected the following features of the neuromuscular sample's morphology: size of the nerve terminals, vesicle population, mitochondrial appearance, Schwann cell's morphology, development and distribution of post-synaptic membrane folds, and nuclear morphology of the different elements of the motor end plate. Besides, the amount of endomysial connective tissue was significantly greater compared to non-intoxicated cases, and these changes were more notorious during the first couple of weeks. 20 to 25 days after the injection, during the recovery phase, we observed nerve terminals with a variable appearance: some completely degenerated, enveloped by Schwann cell processes, and new contacts characterized ultrastructurally for their small size, scarce vesicles, partially enveloped by Schwann cells, early myelinized axons and barely developed synaptic folds. Sixty days after the injection, the axon terminal recovered its normal appearance: synaptic vesicles filled the axon's cytoplasm, and the mitochondria showed normal appearing cristae and electronic densities. We conclude that botulinum neurotoxin type A produces changes related to denervation of the nerve terminals and affects the motor end plate components. Schwann cells play an important role both in the morphofuntional recovery of nerve terminals and in their degradation.


Assuntos
Toxinas Botulínicas Tipo A/toxicidade , Fibras Musculares Esqueléticas/efeitos dos fármacos , Sinapses/efeitos dos fármacos , Animais , Masculino , Camundongos , Microscopia Eletrônica , Fibras Musculares Esqueléticas/diagnóstico por imagem , Músculos do Pescoço/efeitos dos fármacos , Músculos do Pescoço/inervação , Músculos do Pescoço/ultraestrutura , Junção Neuromuscular/diagnóstico por imagem , Junção Neuromuscular/efeitos dos fármacos , Sinapses/ultraestrutura , Ultrassonografia
8.
Pharmacol Toxicol ; 88(6): 313-8, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11453371

RESUMO

Clostridium difficile produces a potent enterotoxin and a cytotoxin, toxin A and toxin B, respectively. These toxins are associated with pseudomembranous colitis and antibiotic-associated diarrhoea. In the present study, we investigated the oedematogenic activity of both toxins, characterizing the time-course and dose-response of this pro-inflammatory event. We also explored the effects of two inhibitors of tumour necrosis factor (TNF) production, thalidomide and pentoxifylline, in neutrophil recruitment and the oedematogenic activity of these toxins. Subplantar injection of toxin A induced paw oedema with a maximal response at 1 microg, reaching a maximal value 9 hr after toxin A challenge (toxin A 1 microg:1.39+/-0.09 ml). Toxin B also showed a dose-dependent oedematogenic activity with a late peak at 24 hr and a maximal response at a dose of 0.1 microg (toxin B 0.1 microg:1.74+/-0.12 ml). Pentoxifylline, but not thalidomide, significantly reduced the oedema induced by Toxin A (pentoxifylline 135 mg/kg:60% of inhibition) and Toxin B (pentoxifylline 135 mg/kg:33.6% of inhibition). Both thalidomide and pentoxifylline were able to significantly reduce neutrophil influx into the peritoneal cavities of rats evoked with Toxin A (thalidomide 45 mg/kg: 53.1% of inhibition; pentoxifylline 45 mg/kg:47.1% of inhibition) and Toxin B (thalidomide 45 mg/kg:46.8% of inhibition; pentoxifylline 45 mg/kg:63.1% of inhibition). This study demonstrates the oedematogenic activities of both toxins with distinct potencies and time-courses. These data also show an inhibitory effect of pentoxifylline in toxin A and B-induced paw oedema. Furthermore, both pentoxifylline and thalidomide significantly inhibited the Clostridium difficile toxins-induced neutrophil migration.


Assuntos
Toxinas Botulínicas Tipo A/toxicidade , Toxinas Botulínicas/toxicidade , Fármacos Dermatológicos/farmacologia , Edema/etiologia , Neutrófilos/efeitos dos fármacos , Pentoxifilina/farmacologia , Talidomida/farmacologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Toxinas Botulínicas/antagonistas & inibidores , Toxinas Botulínicas Tipo A/antagonistas & inibidores , Quimiotaxia de Leucócito/efeitos dos fármacos , Clostridioides difficile/efeitos dos fármacos , Edema/induzido quimicamente , Edema/prevenção & controle , Inibidores Enzimáticos/farmacologia , Masculino , Neutrófilos/metabolismo , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA